No abstract available
Keywords:
B-cell non-Hodgkin lymphoma; CD22+; antibody-drug conjugate; inotuzumab ozogamicin; rituximab.
Publication types
-
Clinical Trial, Phase III
-
Letter
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Female
-
Humans
-
Inotuzumab Ozogamicin
-
Lymphoma, B-Cell / drug therapy*
-
Lymphoma, B-Cell / mortality
-
Lymphoma, B-Cell / pathology
-
Male
-
Middle Aged
-
Rituximab / administration & dosage
-
Rituximab / adverse effects
Substances
-
Antibodies, Monoclonal, Humanized
-
Rituximab
-
Inotuzumab Ozogamicin